Trial Profile
A trial to investigate the efficacy of palivizumab prophylaxis among infants with congenital heart disease (CHD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jun 2016
Price :
$35
*
At a glance
- Drugs Palivizumab (Primary)
- Indications Congenital heart defects
- Focus Therapeutic Use
- 02 Jun 2016 New trial record